Navigation Links
Cord Blood Announces $1 Million Reduction in Long Term Debt
Date:2/12/2009

SANTA MONICA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that between January 1, 2009, and today, it has reduced its long term debt by approximately $1 million.

The Company previously said in press releases and CEO interviews that a major focus is to reduce debt and strengthen the Cord Blood America balance sheet. The mentioned debt was either converted into equity of reduced by principal cash payment. Cord Blood America said the effort to further reduce debt will continue throughout 2009.

CEO Matthew Schissler commented: "It's a start. De-levering our balance sheet coupled with strategic growth and acquisitions are the primary goals for 2009. I'm certain shareholders would agree that removing debts will help put the company in a strong position for long term growth in the stem cell industry."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

    CONTACT:
    Paul Knopick
    E & E Communications
    949/707-5365
    pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
2. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
3. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
4. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
5. CDC Awards NATT Funding to Improve Blood Clot Awareness
6. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
7. Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis
8. Blood Donations in U.S. Testing Positive for Chagas Disease
9. One of Nations Oldest Blood Services Providers Turns to Sysmex America
10. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
11. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017  Eurofins Genomics today announced the ... more customers to receive their primers in a shorter ... in quality found with other providers. Express oligos are ... at no additional fee. Researchers ... studies, including DNA sequencing, genotyping, site-directed mutagenesis, and cloning. ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... an organic compound called fulvic acid that farms, greenhouses and hydroponics operations use ... cannabis are among the fastest growing segments of customers using this high grade ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... of performing routine electrochemical biosensing has increased dramatically. Primarily driven by the ... and quantification of various analytes in complex samples. , Screen-printed ...
(Date:1/12/2017)... Oregon and Pune, India , January 12, 2017 /PRNewswire/ ... vitro Toxicity Testing Market by Type and End Users - Global Opportunity Analysis and ... $7,813 million by 2022 from $2,921 million in 2015, growing at a CAGR of ... ... Allied Market Research Logo ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/4/2017)...  For the thousands of attendees at this year,s International Consumer Electronics ... and biometric measurement devices and services, will be featuring its new line ... A&D Medical,s special CES Exhibit Suite , the new upper arm ... company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):